Lead Product(s) : Ifebemtinib,Garsorasib
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
InxMed Reports Positive Results for Ifebemtinib and Garsorasib in NSCLC
Details : InxMed investigational product IN10018 (Ifebemtinib), a FAK inhibitor, is being evaluated in combination with garsorasib, for the first-line treatment of non-small cell lung cancer.
Brand Name : IN10018
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 30, 2024
Lead Product(s) : Ifebemtinib,Garsorasib
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?